Bio Medica Laboratories Ltd.
Bio Medica Laboratories Ltd. is an SME IPO raising approximately ₹52.43 crores through a combination of fresh issue and offer for sale, listing on NSE SME. The company specialises in contract manufacturing of pharmaceutical parenteral formulations including liquid and dry powder injectables for human and veterinary use.
Overview
About the Company
Bio Medica Laboratories Ltd., incorporated in August 2015, is a pharmaceutical company specialising in the contract manufacturing of parenteral formulations. The company produces a broad range of ethical drugs, generic drugs, and over-the-counter medications in both liquid injectable and dry powder injectable formats, available in single-dose and multi-dose packaging for human and veterinary healthcare. Its product range spans 58 liquid injectable products and 15 dry powder injectable products. Operating exclusively on a B2B basis, the company develops formulations tailored to individual client specifications. It holds Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) certifications from the Food & Drugs Administration, Madhya Pradesh, and operates two manufacturing facilities in Indore, Madhya Pradesh.
Company Details
📋 Objects of Issue (Use of Proceeds)
- › Repayment of existing outstanding loans.
- › Expanding and enhancing existing production capacity by establishing a new manufacturing facility within the current premises.
- › General corporate purposes.
✅ Strengths
- ✓ The company possesses the ability to manufacture multiple product types with a wide and diversified portfolio of parenteral formulations.
- ✓ The promoters, senior management, and workforce bring extensive industry expertise to the business.
- ✓ Strong quality assurance practices backed by GMP and GLP certifications from the Food & Drugs Administration, Madhya Pradesh.
- ✓ The company has developed well-established relationships with its B2B contract manufacturing clients over the years.
⚠️ Risks
- ! The company operates in a highly competitive and fragmented pharmaceutical contract manufacturing segment, which could limit pricing power and market share growth.
- ! The IPO appears aggressively priced relative to its recent financial performance, which may limit near-term upside for investors.
- ! As a B2B contract manufacturer, the company is dependent on client orders and specifications, making it vulnerable to customer concentration risk.
- ! The company carries significant total borrowings of ₹38.17 crores as of November 2025, resulting in a relatively high debt-to-equity ratio.